CN107692187A - One kind improves liver function and reduces postprandial blood sugar ramp-up rate, and gradually reduces the food of postprandial blood sugar - Google Patents
One kind improves liver function and reduces postprandial blood sugar ramp-up rate, and gradually reduces the food of postprandial blood sugar Download PDFInfo
- Publication number
- CN107692187A CN107692187A CN201710722242.5A CN201710722242A CN107692187A CN 107692187 A CN107692187 A CN 107692187A CN 201710722242 A CN201710722242 A CN 201710722242A CN 107692187 A CN107692187 A CN 107692187A
- Authority
- CN
- China
- Prior art keywords
- food
- parts
- blood sugar
- postprandial blood
- sealwort
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 50
- 210000004369 blood Anatomy 0.000 title claims abstract description 47
- 239000008280 blood Substances 0.000 title claims abstract description 46
- 235000000346 sugar Nutrition 0.000 title claims abstract description 34
- 230000000291 postprandial effect Effects 0.000 title claims abstract description 30
- 230000003908 liver function Effects 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 8
- 235000013376 functional food Nutrition 0.000 claims abstract description 4
- 235000013402 health food Nutrition 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 31
- 244000197580 Poria cocos Species 0.000 claims description 26
- 235000008599 Poria cocos Nutrition 0.000 claims description 26
- 244000013123 dwarf bean Species 0.000 claims description 24
- 235000021278 navy bean Nutrition 0.000 claims description 24
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 23
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 14
- 244000302512 Momordica charantia Species 0.000 claims description 13
- 235000009811 Momordica charantia Nutrition 0.000 claims description 13
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims description 13
- 235000018365 Momordica dioica Nutrition 0.000 claims description 13
- 229940069765 bean extract Drugs 0.000 claims description 13
- 238000004806 packaging method and process Methods 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 5
- 235000021485 packed food Nutrition 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 229930014626 natural product Natural products 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 27
- 210000004185 liver Anatomy 0.000 description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 7
- 230000006378 damage Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 108090000279 Peptidyltransferases Proteins 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010019842 Hepatomegaly Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940122816 Amylase inhibitor Drugs 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000185386 Thladiantha grosvenorii Species 0.000 description 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229930185803 charantin Natural products 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000512 lipotoxic effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 230000005982 spleen dysfunction Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of food for improving liver function and assistant hypoglycemic, and in particular to improvement liver function and reduction postprandial blood sugar ramp-up rate from natural products composition, and gradually reduce the food of postprandial blood sugar；The food, can be specifically functional food, and health food is special to cure food；Invention provides the improvement liver function and reduces postprandial blood sugar ramp-up rate simultaneously, and gradually reduces the food making method of postprandial blood sugar.
Description
Technical field
The present invention relates to a kind of protect liver and the food of assistant hypoglycemic, and in particular to the improvement liver function from natural products composition
Postprandial blood sugar ramp-up rate and can be reduced, and gradually reduces the food of postprandial blood sugar, belongs to field of food.
Background technology
Dysfunction of liver refers to that when liver is damaged by some pathogenic factors, liver morphology structural damage can be caused
With the metabolic disorder of liver function；If damage ratio is more serious and extensive (once or prolonged and repeated infringement), can cause obvious
The dysfunction of livers such as metabolism obstacle, function of detoxification reduce, the formation of bile and acatharsia and hemorrhagic tendency change.
Diabetes (DM) are the chronic metabolic diseases using hyperglycaemia as outstanding behaviours.According to the statistics of 2013,
Diabetes mellitus in China number of patients ranks the first in the world to reach more than 9,800 ten thousand.Compared with western countries, China diabetes B patient
The characteristics of blood glucose is composed be exactly raised with postprandial blood sugar based on.A large amount of bases and clinical research find postprandial hyperglycemia in recent years
(PPHG) hazard ratio hyperglycemia is big, it is resolved that the occurrence and development of DM chronic complicating diseases.PPHG is treated, reduces complication
It is increasingly subject to pay attention to.
The experimental results show both at home and abroad at present, and liver function is abnormal many serious with diabetes, metabolic syndrome etc.
Threaten the disease of human life health closely related.Liver is the organ of an important regulation blood glucose, and normal person has eaten thing
After, blood sugar concentration increases.A sugar part in blood provides energy, it is another some a kind of glycogen that cries is converted into by liver
Material, it is stored in liver.If necessary, the glycogen of these storages can be discharged into blood again, prevent blood glucose from dropping too low.This
Outside, liver can also participate in the metabolism operating of human body by participating in various metabolic processes.So when habits and customs are bad etc. various
When reason causes hepatic disease, normal glycometabolism may be all influenceed, causes IGT, or diabetes.If suffer from
Person may also have high fat of blood and fatty liver simultaneously, and liver function sustains damage, and can further influence the feelings of metabolism of blood glucose again in turn
Condition, and then aggravate diabetes.
Diabetes can be also had an impact to the infringement of liver function as a kind of disease of incretion, be mainly manifested in
Under several aspects, hepatic sclerosis：Diabetic liver hardening is not rare.Its pathogenesis may have with glucose toxicity and lipotoxicity
Close；Hepatomegaly：Hepatomegaly can occur for diabetic, be more common in the youth for being in a bad way and not controlling or children's glycosuria especially
Patient, poor blood glucose control or ketosis patient's hepatomegaly are more than 60%；Fatty liver：Diabetic about 50% is associated with fat
Fat liver, both may reciprocal causation.Work as insufficient insulin, when glycemic control is unsatisfied with, easily suffer from fatty liver；Gallbladder disease：Capsule
Increase is most common change, higher than non-diabetic people 3 times, this and diabetes autonomic nervous dysfunction, causes gall-bladder to relax
Contracting function is relevant, the gall-bladder of enlargement, and bile is more easily to develop into cholelithiasis, cholecystitis etc.；Virus hepatitis：Diabetic
Hepatitis illness rate, it is higher than common people 2-4 times, and diabetes merge chronic hepatitis C in increasing trend, on the other hand, by
One of in diabetic's immunologic hypofunction, Abwehrkraft des Koepers weakens, and the reason for cause hepatitis to occur；Drug liver
It is scorching：Investigation display, diabetic do not go to regular hospital to see a doctor, arbitrarily buy medicine, do not know poisonous side effect of medicine, be to cause hepatic injury
The reason for.
In summary, interacted between liver function and diabetes, liver is that sugar, fat and protein metabolism are most heavy
The place wanted, and the main portions of insulin action and insulin catabolism, so liver function and sugar, fat and albumen
Matter metabolism is in close relations, and generation and development to diabetes have an impact；In terms of another, diabetes are also easy to
Fat metabolic disturbance and fatty liver are caused, influences liver function, liver enlargement is caused, dysfunction of liver, even results in hepatic sclerosis.
Improve liver function at this stage and reduce postprandial blood sugar ramp-up rate, and gradually reduce postprandial blood sugar and be required for taking for a long time
With medicine, and two kinds of diseases interact, and this just often results in therapeutic process and attended to one thing and lose sight of another, and in diabetic, merge
Liver function problem ratio is far above countries such as America and Japan.Division of endocrinology of attached Changhai hospital of The 2nd Army Medical College professor Zou great Jin refers to
Go out, treating diabetes are extremely complex, it is desirable to which doctor and patient must especially pay attention to the safety problem of liver function.The Central China University of Science and Technology
Attached division of endocrinology of Concord Hospital professor Chen Lulu of Tongji Medical Institute points out, when diabetes merge lesions of liver and kidney patient medication, meeting
The situations such as the difficult adjustment of dosage, the difficult survey of effect are faced, are damaged moreover, once there is liver kidney, many OHAs cannot be used.
One kind can be long-term use of, especially can be food, does not have new side reaction to produce to people, while can improve liver function
Can and and reduce postprandial blood sugar ramp-up rate, and gradually reduce postprandial blood sugar, this just seems particularly urgent for clinical patient
Cut.
The content of the invention
It is an object of the invention to provide a kind of food that can be long-term use of, while liver function and and reduction meal can be improved
Blood glucose rise speed afterwards, and gradually reduce postprandial blood sugar.The food, can be specifically functional food, and health food is special to cure
Food.
Realizing the technical scheme of the object of the invention is：A kind of food, it contains following component：Poria cocos, navy bean, sealwort,
Balsam pear, chitosan oligosaccharide；The food, can be specifically functional food, and health food is special to cure food.
Described food, its composition included are：Poria cocos 500-1500 parts, navy bean 500-1500 parts, sealwort 100-300
Part, balsam pear 100-300 parts, chitosan oligosaccharide 100-300 parts.
The composition that food includes is：1000 parts of Poria cocos, 1000 parts of navy bean, 200 parts of sealwort, 200 parts of balsam pear, chitosan oligosaccharide
200 parts.
Contain tuckahoe extracts 0.5-1.5g, navy bean extract 0.5-1.5g, Rhizoma Polygonati extract per independent packaged food
0.1-0.3g, Bitter Melon P.E 0.1-0.3g, chitosan oligosaccharide 0.1-0.3g.
Contain tuckahoe extracts 1.0g, navy bean extract 1.0g, Rhizoma Polygonati extract 0.2g, balsam pear per independent packaged food
Extract 0.2g, chitosan oligosaccharide 0.2g.
The food is also containing appropriate edible additive.The edible additive can be flavouring such as
Sugar, chocolate, Momordica grosvenori etc.；Thickener such as xanthans, gelatin, sodium alginate, guar gum etc.；Water-soluble dietary fiber is for example oligomeric
Lactose, xylo-oligosaccharide, soyabean oligosaccharides, resistant dextrin etc..
Described food is prepared by the following method：
(1) sterilization processing, is carried out using ultraviolet irradiation to supplementary material,
(2) it is standby then by each component weight weighing in formula, by broken 40 mesh sieves excessively afterwards of the supplementary material for having particle or caking
With；
(3), load weighted supplementary material is placed in mixer together and mixed；Cross 40 mesh sieves；
(4) products obtained therefrom, is subjected to quantitative separating or tabletting, packaging bags or canned packaging.
The result of moisture measurement after being prepared according to food, can increase step：By the grain after screen cloth excessively at 60~85 DEG C
At a temperature of dry, while being stirred makes each component be sufficiently mixed uniformly, dries to product moisture content (weight) less than 5%.
Food form is powdery, graininess, sheet.
Poria cocos of the present invention can be tuckahoe extracts, and navy bean can be navy bean extract, and sealwort can be yellow
Essence extract, balsam pear can be Bitter Melon P.Es.Pachymaran >=20% in tuckahoe extracts, Rhizoma Polygonati extract specification are 30:
1, Charantin >=10% in Bitter Melon P.E, chitosan oligosaccharide >=80%. in chitosan oligosaccharide
In the present invention, tuckahoe extracts, can under diarrhea caused by insufficiency of the spleen dysfunction of the spleen in transportation and transformation, band, there is the effect of giving consideration to both the incidental and fundamental
With the adjuvant for for tonifying lung spleen, controlling the deficiency of vital energy；Energy mental-tranquilization, available for diseases such as confused and worried, palpitaition, insomnias；For urine not
Profit, oedema etc..The kidney bean albumen contained in navy bean extract is a kind of natural amylase inhibitor, effectively reduces 66% and forms sediment
Powder absorbs；It is mainly used in treating obesity, diabetes, reduces heat absorption, reduce glycemic index, reduces starch-sugar-fat and turn
Change.Chitosan oligosaccharide is referred to as " the 6th vital principle " immunological regulation to human body, antitumor, lowering blood pressure and blood fat, reduce liver and
Cholesterol, regulation blood glucose, relieving alcoholism and protecting liver, elimination fatty liver and other different physiological roles important roles in serum.It is yellow
Essence is sweet, mild-natured, and effect is slow, can make the product of long term usage nourishing.With boosting qi and nourishing yin, invigorating the spleen moistening lung is antifatigue, anti-oxidant to wait work(
Effect, to reducing blood glucose, improving diabetes has remarkable effect.Bitter Melon P.E has good effect of lowering blood sugar, is known as plant pancreas islet
Element, full component extract, compare for type-II diabetes, and Western medicine antidiabetic drug, have no toxic side effect.
The present invention has advantages below compared with prior art：Food prepared by the present invention can be long-term use of, to improving liver
Function has special efficacy, can reduce postprandial blood sugar ramp-up rate, and gradually reduces postprandial blood sugar, and opsonic action is played to body.
Convenient food prepared by the present invention carries, and is adapted to take frequently as ordinary food day；The preparation method of the present invention is simple simultaneously, easily
Operation, is easy to popularity, it is easy to accomplish standardization, standardization, factorial praluction.
Embodiment
It is described in further detail with reference to embodiment and to the present invention.
Embodiment 1 prepares a kind of powdered food
Its preparation method comprises the following steps：
(1) sterilization processing, is carried out using ultraviolet irradiation to supplementary material；
(2) 40 mesh sieves are crushed after, the supplementary material for having particle or caking is weighed, are then claimed by each component weight in formula
Amount：Poria cocos 10Kg, navy bean 10Kg, sealwort 2Kg, balsam pear 2Kg, chitosan oligosaccharide 2Kg are standby；
(3), Poria cocos, navy bean, sealwort, balsam pear, chitosan oligosaccharide are placed in mixer and mix by load weighted；Cross 40 mesh
Sieve.
(4) products obtained therefrom, is subjected to quantitative separating into 10000 parts,
(5), packaging bags or canned packaging.
Embodiment 2 prepares a kind of powdered food
Its preparation method comprises the following steps：
(1) sterilization processing, is carried out using ultraviolet irradiation to supplementary material；
(2) 40 mesh sieves are crushed after, the supplementary material for having particle or caking is weighed, are then claimed by each component weight in formula
Amount：Tuckahoe extracts 10Kg, navy bean extract 10Kg, Rhizoma Polygonati extract 2Kg, Bitter Melon P.E 2Kg, chitosan oligosaccharide 2Kg are standby；
(3), load weighted tuckahoe extracts, navy bean extract, Rhizoma Polygonati extract, Bitter Melon P.E, chitosan oligosaccharide are put
Mixed in mixer；Cross 40 mesh sieves；
(4) products obtained therefrom, is subjected to quantitative separating into 10000 parts；
(5), packaging bags or canned packaging.
Embodiment 3 prepares a kind of granule state food
Its preparation method comprises the following steps：
(1) sterilization processing, is carried out using ultraviolet irradiation to supplementary material；
(2) 40 mesh sieves are crushed after, the supplementary material for having particle or caking is weighed, are then claimed by each component weight in formula
Amount：Tuckahoe extracts 10Kg, navy bean extract 10Kg, Rhizoma Polygonati extract 2Kg, Bitter Melon P.E 2Kg, chitosan oligosaccharide 2Kg are standby；
(3), load weighted tuckahoe extracts, navy bean extract, Rhizoma Polygonati extract, Bitter Melon P.E, chitosan oligosaccharide are put
Mixed in mixer；Cross 40 mesh sieves.
(4), 95% ethanol wet granulation, the sieving of 20 eye mesh screens；
(5), the material after screen cloth excessively is dried at a temperature of 70~75 DEG C, dries to product moisture content (weight) and is less than
5%, cross 20 eye mesh screens after it is standby；
(6) gained particle, is subjected to quantitative separating, is averagely distributed into about 10000 parts, packaging bags or canned bag
Dress.
Embodiment 4 prepares a kind of sheet-like food of compacting
Its preparation method comprises the following steps：
(1) sterilization processing, is carried out using ultraviolet irradiation to supplementary material.
(2) 40 mesh sieves are crushed after, the supplementary material for having particle or caking is weighed, are then claimed by each component weight in formula
Amount：Tuckahoe extracts 10Kg, navy bean extract 10Kg, Rhizoma Polygonati extract 2Kg, Bitter Melon P.E 2Kg, chitosan oligosaccharide 2Kg are standby；
(3), load weighted tuckahoe extracts, navy bean extract, Rhizoma Polygonati extract, Bitter Melon P.E, chitosan oligosaccharide are put
Mixed in mixer, cross 40 mesh sieves；
(4), 95% ethanol wet granulation, the sieving of 20 eye mesh screens；
(5), the material after screen cloth excessively is dried at a temperature of 70~75 DEG C, dries to product moisture content (weight) and is less than
5%, cross 20 eye mesh screens after it is standby；
(6) the progress tabletting of gained particle, is made about 100000, packaging bags or canned packaging.
Embodiment 5 prepares a kind of food for adding appropriate edible additive
Its preparation method comprises the following steps：
(1) sterilization processing, is carried out using ultraviolet irradiation to supplementary material；
(2) 40 mesh sieves are crushed after, the supplementary material for having particle or caking is weighed, are then claimed by each component weight in formula
Amount：Tuckahoe extracts 10Kg, navy bean extract 10Kg, Rhizoma Polygonati extract 2Kg, Bitter Melon P.E 2Kg, chitosan oligosaccharide 2Kg are standby；
(3), the appropriate edible additive each component weight weighing that will be added in advance：Fructus Monordicae extract 0.3Kg, xanthan
Glue 1.5Kg, resistant dextrin 36.2Kg.
(3), load weighted Rhizoma Polygonati extract, Bitter Melon P.E, chitosan oligosaccharide, Fructus Monordicae extract, xanthans are placed in mixed
Mixed in conjunction machine；Cross 40 mesh sieves；
(4) load weighted tuckahoe extracts, navy bean extract, resistant dextrin, are added into the thing that the 3rd step has mixed sieving
In material, it is placed in mixer and mixes, crosses 40 mesh sieves；
(5) products obtained therefrom, is subjected to quantitative separating into 10000 parts；
(6), packaging bags or canned packaging.
Beneficial effects of the present invention are further illustrated below by way of test example.
Test example 1 improves the case observation of liver function
1st, patient profile：Selection University Of Qingdao affiliated hospital meets the outpatient of liver function damage diagnostic criteria totally 40
Example.Wherein male 31, women 9；The course of disease 6~15 months, it is average 9.34 months；It is 36~61 years old age, average 48.12 years old；
All patients take western medicines in treatment history before food treatment of the present invention is received, and the medication treatment time is more than 3 months.
2nd, case selection standard：A liver function damage diagnostic criteria：A dulls pain in liver are with weak；B glutamic-pyruvic transaminase (ALT) and
Paddy acyl transpeptidase (GGT) is slight (≤normal 3 times) or moderate (>Normal 3 times) rise；The c courses of disease exceed half a year.
3rd, case exclusion standard：Hepatitis caused by having the factors such as clear and definite medicine, ethylism；Be associated with severe cardiac, brain,
The severe primary such as lung, kidney or hemopoietic system disease or mental patient；The gestational period or women breast-feeding their children；Age is more than 70 years old
Or under-18s；Uncooperative or interruption curer is not included in this research range.
4th, observation index：A securities are observed：A blood pressures, respiration rate per minute, heart rate, pulse；B whole bloods, urine
Analysis, stool for routine；C electrocardiograms, renal function.
B curative effects are observed：A clinical symptoms, sign；B liver functions, it is main to observe the most sensitive index glutamic-pyruvic transaminase of liver function
And paddy acyl transpeptidase (GGT) (ALT)；Detected using performance rate method.
5th, efficacy assessment standard：A is effective：Cardinal symptom disappears or basic disappearance, liver function glutamic-pyruvic transaminase (ALT) and paddy
Acyl transpeptidase (GGT) is down to normal range (NR).
B is effective：Cardinal symptom partial disappearance or obvious mitigation, liver function glutamic-pyruvic transaminase (ALT)
Decline more than 50% with paddy acyl transpeptidase (GGT) initial value；
C is invalid：Cardinal symptom improves unobvious, and liver function glutamic-pyruvic transaminase (ALT) and paddy acyl transpeptidase (GGT) decline not
Reach effective standard.
Treatment method：
(1) classified data：Selected personnel are divided into treatment group and control group according to principle of randomization.Treatment group 20,
Male 15, women 5；The course of disease 6~15 months, it is average 9.45 months；It is 35~59 years old age, average 49.76 years old；Control group 20
Example, male 16, women 4；The course of disease 7~14 months, it is average 9.62 months；It is 40~60 years old age, average 49.83 years old.Two groups
Case is statistically analyzed in sex, the course of disease, age etc., difference there are no significant meaning (P>0.05), there is comparativity.
(2) application method：The pulvis of the method preparation according to embodiment in embodiment 2 is given by treatment group, and every time 1
Bag, 3 times a day；Control group gives the placebo (starch) equally packed.
Two groups with 30 days for a course for the treatment of, evaluate curative effect after a course for the treatment of.
(3) statistical method：Statistical analysis is carried out using statistical software S P S S17.0.Measurement data is examined using x2,
Enumeration data is examined using t, confidential interval 95%, P<0.05 is significant difference, has statistical significance.
5th, result:
(1) treatment group's (present composition) relatively see the table below 1 with control group curative effect.
Table 1：Treatment group is compared with control group curative effect
Two groups using effective+effective and as virtual value calculating total effective rate.Treatment group's total effective rate is 85.0%, right
It is 15.0% according to group, two groups are compared, and have significant difference (P<0.05).The effect of illustrating the present composition is better than control
Group.
(2) between treatment group and control group ALT GGT before and after treatment compared with see the table below 2.
Table 2：Treatment group and control group A LT GGT before and after treatment compared with
Examined using t：Two groups of pretherapy and post-treatment ALT, GGT compare, P ＜ 0.05；Front and rear contrast in group, P ＜ 0.05.
Two groups of pretherapy and post-treatment ALT and GGT have significant difference (P<0.05) present composition and control drug, are shown
Liver function damage state can be improved.ALT and GGT after the present composition treatment P ＜ 0.05, have compared with control group
Significant difference, the effect of showing the present composition, are better than control group.
Influence of the present invention of test example 2 to after-dinner blood sugar of diabetes patients
Testing crew：Diabetes B patient 48 is selected, it is bisected into two groups at random.Wherein control group totally 24, year
It is minimum 30 years old of age, maximum 60 years old, average (45.60 ± 8.96) year, man 14, female 10.Treatment group totally 24, age minimum 29
Year, maximum 59 years old, average (46.63 ± 8.31) year, man 15, female 9.
Full complement meets the diabetes B diagnostic criteria that the World Health Organization in 2007 promulgates.Two groups of sexes, ages
Compare etc. general information, no significant difference (P>0.05), there is comparativity.
The daily breakfast, lunch and dinner of control group are edible to be carried out according to former mode, and treatment group daily three is given according to embodiment before the meal
Pulvis prepared by the method for middle embodiment 2,1 wrap every time；Two groups of personnel before the meal and postprandial 5min, survey for 0.5,1,2,3 hour respectively
Its blood glucose, be carried out continuously ten days, during experiment in two groups of personnel, dinner species it is identical with amount, the species of hypoglycemic medicine and
Dosage keeps constant；Subsequent two groups of equal continual cures, with 90 days for a course for the treatment of, evaluation is to postprandial blood after a course for the treatment of
The influence of sugar.
3. result of the test：
Table 1：The change (x ± s) of control group and treatment group's dining day part blood glucose (mmol/L)
As known from Table 1, control group postprandial blood sugar is significantly raised, and treatment group's postprandial blood sugar rate of climb is significantly lower than control group
Postprandial blood sugar, and treatment group's blood glucose value is more steady, no hyperglycaemia peak value.
The change (x ± s) of control group and treatment group's postprandial blood sugar (mmol/L) after 2 one courses for the treatment of of table
As known from Table 2, unobvious are changed before control group postprandial blood sugar and treatment, treatment group's postprandial blood sugar is significantly lower than the course for the treatment of
Postprandial blood sugar before beginning, treatment group's postprandial plasma glucose level are more steady after a course for the treatment of.
Claims (10)
1. a kind of food, it is characterised in that food includes following component：Poria cocos, navy bean, sealwort, balsam pear, chitosan oligosaccharide；The food
Product, can be specifically functional foods, and health food is special to cure food.
2. food according to claim 1, it is characterised in that the composition that food includes is：Poria cocos 500-1500 parts, Bai Yun
Beans 500-1500 parts, sealwort 100-300 parts, balsam pear 100-300 parts, chitosan oligosaccharide 100-300 parts.
3. food according to claim 2, it is characterised in that the composition that food includes is：1000 parts of Poria cocos, navy bean
1000 parts, 200 parts of sealwort, 200 parts of balsam pear, 200 parts of chitosan oligosaccharide.
4. food according to claim 1, it is characterised in that contain Poria cocos 0.5-1.5g, navy bean per independent packaged food
0.5-1.5g, sealwort 0.1-0.3g, balsam pear 0.1-0.3g, chitosan oligosaccharide 0.1-0.3g.
5. food according to claim 4, it is characterised in that contain Poria cocos 1.0g, navy bean per independent packaged food
1.0g, sealwort 0.2g, balsam pear 0.2g, chitosan oligosaccharide 0.2g.
6. food according to claim 1, it is characterised in that the food is also containing appropriate edible additive.
7. according to any described food of claim 1-6, it is characterised in that Poria cocos can be tuckahoe extracts, and navy bean can be with
It is navy bean extract, sealwort can be Rhizoma Polygonati extract, and balsam pear can be Bitter Melon P.E.
8. composition according to claim 7, it is characterised in that described food is prepared by the following method：
(1) sterilization processing, is carried out using ultraviolet irradiation to supplementary material,
(2) it is standby then by each component weight weighing in formula, by broken 40 mesh sieves excessively afterwards of the supplementary material for having particle or caking；
(3), load weighted supplementary material is placed in mixer together and mixed, crosses 40 mesh sieves；
(4) products obtained therefrom, is subjected to quantitative separating or tabletting, packaging bags or canned packaging.
9. food according to claim 7, it is characterised in that the food form is powdery, graininess, sheet.
10. food according to claim 7, it is characterised in that the food prepare be used for prevent and improve liver function and
Postprandial blood sugar ramp-up rate is reduced, and gradually reduces the application of postprandial blood sugar.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710722242.5A CN107692187A (en) | 2017-08-22 | 2017-08-22 | One kind improves liver function and reduces postprandial blood sugar ramp-up rate, and gradually reduces the food of postprandial blood sugar |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710722242.5A CN107692187A (en) | 2017-08-22 | 2017-08-22 | One kind improves liver function and reduces postprandial blood sugar ramp-up rate, and gradually reduces the food of postprandial blood sugar |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107692187A true CN107692187A (en) | 2018-02-16 |
Family
ID=61169809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710722242.5A Pending CN107692187A (en) | 2017-08-22 | 2017-08-22 | One kind improves liver function and reduces postprandial blood sugar ramp-up rate, and gradually reduces the food of postprandial blood sugar |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107692187A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19980033798A (en) * | 1996-11-01 | 1998-08-05 | 김상조 | Pharmaceutical composition for the treatment of diabetes |
| CN102860451A (en) * | 2012-09-10 | 2013-01-09 | 厦门金日制药有限公司 | Composite with function of assisting in decreasing blood glucoses and products thereof |
| CN105211849A (en) * | 2015-08-24 | 2016-01-06 | 吴峒何 | A kind of health food of prevention and therapy diabetes |
| CN105943992A (en) * | 2016-07-14 | 2016-09-21 | 李加义 | Traditional Chinese medicine composition for treating diabetes |
| CN106820169A (en) * | 2017-02-28 | 2017-06-13 | 李洋 | Special medical food formula and its production technology that a kind of diabetic is applicable |
| CN106901367A (en) * | 2017-03-14 | 2017-06-30 | 张勇 | The composition and preparation method and purposes of a kind of balance blood sugar |
-
2017
- 2017-08-22 CN CN201710722242.5A patent/CN107692187A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19980033798A (en) * | 1996-11-01 | 1998-08-05 | 김상조 | Pharmaceutical composition for the treatment of diabetes |
| CN102860451A (en) * | 2012-09-10 | 2013-01-09 | 厦门金日制药有限公司 | Composite with function of assisting in decreasing blood glucoses and products thereof |
| CN105211849A (en) * | 2015-08-24 | 2016-01-06 | 吴峒何 | A kind of health food of prevention and therapy diabetes |
| CN105943992A (en) * | 2016-07-14 | 2016-09-21 | 李加义 | Traditional Chinese medicine composition for treating diabetes |
| CN106820169A (en) * | 2017-02-28 | 2017-06-13 | 李洋 | Special medical food formula and its production technology that a kind of diabetic is applicable |
| CN106901367A (en) * | 2017-03-14 | 2017-06-30 | 张勇 | The composition and preparation method and purposes of a kind of balance blood sugar |
Non-Patent Citations (4)
| Title |
|---|
| 冯延民: "《壳寡糖与人类健康》", 31 March 2008, 吉林大学出版社 * |
| 孙晶丹: "《食物相宜相克速查图典》", 31 January 2015, 重庆出版社 * |
| 李向吉: "《常用中药材应用与栽培》", 30 July 2014, 甘肃科学技术出版社 * |
| 杨建峰: "《养生堂》", 31 May 2017, 江西科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019101804A4 (en) | Traditional Chinese medicine medical nutrition therapy-based composition for treating diabetes, and application | |
| CN105077236B (en) | Compound special meals nutrient powder of the highland barley of auxiliary hyperglycemic and preparation method thereof | |
| CN101057643B (en) | Rice with blood sugar reducing function | |
| CN103416663A (en) | Whole-grain complete-nutrition formulation food for diabetics | |
| CN106901367A (en) | The composition and preparation method and purposes of a kind of balance blood sugar | |
| CN107212256A (en) | A kind of meal replacement powder with function of blood sugar reduction and preparation method thereof | |
| CN107198767A (en) | It is a kind of to be used to prevent three high red yeast rice balsam pear complex peptides pieces | |
| CN105558198A (en) | Health-care tea capable of reducing blood sugar and preparation method of health-care tea | |
| CN106418143A (en) | Composition for improving sleep and vision and application thereof | |
| CN107568375A (en) | A kind of adlay slim tea and preparation method thereof | |
| CN107582738A (en) | A kind of Chinese medicine for losing weight composition and preparation method thereof | |
| CN102204650B (en) | Health staple food with low glycemic index, its preparation method and application in blood sugar reduction | |
| CN106819799A (en) | A kind of health-care rice flour of confession infantile spleen deficiency edible for patients and preparation method thereof | |
| CN103535625A (en) | Food for regulating and controlling blood glucose and preparation method thereof | |
| CN115474691A (en) | Medicinal and edible nutritious food for reducing blood sugar of diabetes and preparation method thereof | |
| CN107692187A (en) | One kind improves liver function and reduces postprandial blood sugar ramp-up rate, and gradually reduces the food of postprandial blood sugar | |
| CN108042739A (en) | It is a kind of to be used to prevent composition of diabetes and its preparation method and application | |
| CN107136499A (en) | Compound preparation for enhancing immunity of tumor patients after operation | |
| CN103933282B (en) | A kind of Chinese medicinal capsule for treating diabetes | |
| CN106692667A (en) | Composition with effects of reducing blood pressure, blood fat and blood glucose and use of composition | |
| CN108420983B (en) | Edible additive with blood sugar reducing function and preparation method and application thereof | |
| CN109731089A (en) | A kind of composition and its preparation method and application adjusting liver-stomach disharmony | |
| CN103798596A (en) | Total nutrient formula food suitable for patients with cardiovascular and cerebrovascular diseases | |
| CN108813305A (en) | A kind of highland barley function conditioning composition | |
| CN108157969A (en) | A kind of blood-enriching face-nourishing composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180216 |
|
| RJ01 | Rejection of invention patent application after publication |